These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea. Leahy RG; Serio AW; Wright K; Traczewski MM; Tanaka SK J Glob Antimicrob Resist; 2022 Sep; 30():96-99. PubMed ID: 35500838 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials. Skinner AM; Petrella LA; Cheknis A; Johnson S J Antimicrob Chemother; 2023 Jul; 78(7):1779-1784. PubMed ID: 37279600 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile. Murray B; Wolfe C; Marra A; Pillar C; Shinabarger D J Antimicrob Chemother; 2020 Aug; 75(8):2149-2155. PubMed ID: 32285102 [TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016 [TBL] [Abstract][Full Text] [Related]
8. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Pfaller MA; Huband MD; Shortridge D; Flamm RK Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071045 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172 [TBL] [Abstract][Full Text] [Related]
10. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17. Gargis AS; Karlsson M; Paulick AL; Anderson KF; Adamczyk M; Vlachos N; Kent AG; McAllister G; McKay SL; Halpin AL; Albrecht V; Campbell D; Korhonen LC; Elkins CA; Rasheed JK; Guh AY; McDonald LC; Lutgring JD; Clin Infect Dis; 2023 Mar; 76(5):890-896. PubMed ID: 36208202 [TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. Corbett D; Wise A; Birchall S; Warn P; Baines SD; Crowther G; Freeman J; Chilton CH; Vernon J; Wilcox MH; Vickers RJ J Antimicrob Chemother; 2015; 70(6):1751-6. PubMed ID: 25652750 [TBL] [Abstract][Full Text] [Related]
12. Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011. Pfaller MA; Huband MD; Rhomberg PR; Flamm RK Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223386 [TBL] [Abstract][Full Text] [Related]
13. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. Huband MD; Pfaller MA; Shortridge D; Flamm RK J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698 [TBL] [Abstract][Full Text] [Related]
14. A US-based national surveillance study for the susceptibility and epidemiology of Snydman DR; McDermott LA; Thorpe CM; Goldstein EJC; Schuetz AN; Johnson S; Gerding DN; Gluck L; Bourdas D; Carroll KC; Lancaster CK; Garey KW; Wang Q; Walk ST; Duperchy E Antimicrob Agents Chemother; 2023 Oct; 67(10):e0034923. PubMed ID: 37728368 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. Xiao M; Huang JJ; Zhang G; Yang WH; Kong F; Kudinha T; Xu YC BMC Microbiol; 2020 Nov; 20(1):350. PubMed ID: 33198626 [TBL] [Abstract][Full Text] [Related]
16. Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019-2021. Tsai CS; Lu PL; Lu MC; Hsieh TC; Chen WT; Wang JT; Ko WC J Microbiol Immunol Infect; 2024 Apr; 57(2):320-327. PubMed ID: 38135646 [TBL] [Abstract][Full Text] [Related]